A measurable biological indicator used to assess normal processes, disease states, or responses to treatment. IGF-1 levels are a common biomarker for growth hormone secretagogue therapy.
"Biomarker" is filed under Evidence & Research in the PeptideAtlas glossary, alongside 14 other terms in that group.
The term applies directly to 1 compound profile here: Adrenomedullin (evidence D). Each profile states the strength of the human evidence rather than only what the compound is claimed to do.
A study where participants are randomly assigned to receive either the treatment or a control (placebo or standard care). The gold standard for establishing causality in medical research.
The first stage of clinical testing in humans, typically involving 20-100 healthy volunteers. Tests safety, dosage, and side effects. Most peptides in the research pipeline are at or before this stage.
Clinical trials involving 100-300 patients with the target condition. Tests efficacy and further evaluates safety. Provides initial evidence of whether a peptide works for its intended purpose.
Compounds where this applies: Adrenomedullin.
More Evidence & Research terms: Randomized Controlled Trial (RCT), Phase I Trial, Phase II Trial, Phase III Trial, Systematic Review, Meta-Analysis, In Vitro, In Vivo, Preclinical, Placebo Effect, p-Value, Endpoint, Observational Study, Publication Bias.